Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharmacies
NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.
Tudorza is a long-acting anticholinergic recently approved by the U.S. Food and Drug Administration (FDA) for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Tudorza is the first long-acting inhaled anticholinergic approved by the FDA in over 8 years for COPD and is administered twice daily through the preloaded, multidose Pressair inhaler.
Almirall granted commercialization rights in the U.S. for aclidinium to Forest Laboratories, Inc., Forest and Almirall will co-promote aclidinium in Canada. Almirall maintains rights for the rest of the world.
Visit www.tudorza.com for more information about Tudorza Pressair.
Source: Forest Laboratories, Inc.